Med vs VizaView
Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.
Med
This app assists healthcare professionals in managing heart failure medications. It provides evidence-based algorithms and recommendations for initiating, titrating, and monitoring six common drug classes based on Canadian guidelines.
- Medication initiation and titration guidance
- Dosing information
- Evidence-based algorithms
- Clinical pearls
- Drug class specific recommendations
- References
Read full descriptionHide full description
The Med-HF App supports healthcare professionals in the initiation, titration, assessment and monitoring of 6 drug classes commonly used to treat heart failure: ACEIs/ARBs, Beta-Blockers, MRA: Mineralocorticoid Receptor Antagonist, ARNI: Angiotensin Receptor Blocker / Neprilysin Inhibitor, Ivabradine, Diuretics. This App interactively walks healthcare professionals through evidence-based algorithms, specific to these 6 drug classes, and recommends appropriate actions and considerations based on 2018 Canadian Cardiovascular Society Heart Failure Guidelines. Features: • Recommendations for medication initiation, titration, assessment and monitoring • Dosing information • References • Clinical pearls • General approach and drug class algorithms
VizaView
Read full descriptionHide full description
VizaView is a Vizamyl™ case-based review application designed to enhance the case reading ability of trained imagers. This tool is intended for informational purposes only and is not a replacement or substitute for the required Vizamyl™ Reader Training Program. If you have clinical or scientific questions regarding the content of this app, please contact GE HealthCare at (800) 654-0118 (option 2, option 3) or via email medical.affairs@gehealthcare.com.
Screenshots
Verdict
The clearest difference is iOS requirement: Med at 11.0 against VizaView's 15.0. On price, update cadence, ads and in-app purchases there is nothing between them.
Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS
Both are free to download. Neither carries in-app purchases, so what you see is what you pay.
Med ships an update every 35 months, VizaView every 31 months. The most recent releases landed on October 29, 2026 and October 27, 2026 respectively.
| Parameter | Med | VizaView |
|---|---|---|
| Price | Free | Free |
| Positive reviews | 100.0% of reviews | — |
| Update frequency | Every 35 months | Every 31 months — better |
| Ads | No | No |
| In-app purchases | No | No |
| Monetization | Free | — |
| Devices | iPhone, iPod | iPhone, iPad, iPod — better |
| Requires iOS | 11.0 — better | 15.0 |
| Further details — not scored | ||
| Size | 15 MB | 376 MB |
| Age rating | 12+ | 4+ |
| Developer | AHS | GE HealthCare Technologies Inc |
In-app purchases
Med
No in-app purchases
VizaView
No in-app purchases
